The Australian Therapeutic Goods Administration (ATGA) has given the green light for the EYLEA Injection to be an approved treatment for patients suffering from neovascular age-related macular degeneration. Bayer HealthCare and Regeneron Pharmaceuticals, Inc. are planning to launch EYLEA in Australia in the second part of 2012. The ATGA gave its approval upon completion of the Phase III clinical trials.The recommended dosing is 2 milligrams via intravitreal injection per month for three consecutive months followed by 2 mg injections every two months. In comparison, patients currently receiving Lucentis injections must take monthly injections to achieve the same benefit. EYLEA had previously been approved for treating wet macular degneration in the U.S. by the FDA back in November 2011. Regeneron is currently seeking approval in the U.S. for treating retinal vein occlusion with EYLEA.